Dendritic cell-based vaccine targeting aspartate- β-hydroxylas represents a promising therapeutic strategy for HCC

Immunotherapy, Ahead of Print.

Source: Immunotherapy - October 13, 2019 Category: Allergy & Immunology Authors: Yujiao Zhou Chengmin Li Guo Shi Xiaolei Xu Xue Luo Yuanling Zhang Jingjie Fu Limin Chen Aizhong Zeng Source Type: research